Merck’s breakthrough COVID pill faces a risk: the virus could outsmart it

Merck & Co.’s experimental pill for Covid-19 should be accompanied by other treatments as soon as they’re available to cut the risk of drug resistance that would limit its effectiveness, Wellcome foundation director Jeremy Farrar said.